Evidence map›Paper›PMID 33995379›Full record

ArticleFrontiers in immunology2021

Comprehensive Analysis of Myeloid Signature Genes in Head and Neck Squamous Cell Carcinoma to Predict the Prognosis and Immune Infiltration.

Zhifeng Liu, Diekuo Zhang, Chao Liu, Guo Li, Huihong Chen, Hang Ling, Fengyu Zhang, Donghai Huang, Xingwei Wang, Yong Liu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Trial
  3. ZNF683Nature communications · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhifeng LiuDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.
Diekuo ZhangDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.
Chao LiuDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.
Guo LiDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.
Huihong ChenDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.
Hang LingDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.
Fengyu ZhangDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.
Donghai HuangDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.
Xingwei WangDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.
Yong LiuDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.
Xin ZhangDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid cells are a major heterogeneous cell population in the tumor immune microenvironment (TIME). Imbalance of myeloid response remains a major obstacle to a favorable prognosis and successful immune therapy. Therefore, we aimed to construct a risk model to evaluate the myeloid contexture, which may facilitate the prediction of prognosis and immune infiltration in patients with head and neck squamous cell carcinoma (HNSCC). In our study, six myeloid signature genes (including

Indexed as

Biomarkers, TumorGene Expression Regulation, NeoplasticAdultAgedDisease ManagementDisease SusceptibilityFemaleHumansImmunotherapyLymphocytes, Tumor-InfiltratingMaleMiddle AgedMyeloid CellsNeoplasm GradingNeoplasm StagingPrognosisBiomarkers, Tumorhead and neck squamous cell carcinomaimmune infiltrationimmunotherapymyeloid cellsprognosistumor immune microenvironment

Identifiers

PMID33995379
PMCPMC8116959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.